3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leiomyoma
2
Breast Neoplasms
2
Vomiting
1
Vascular Malformations
1
Uterine Neoplasms
1
Resectable Pancreatic Ductal Adenocarcinoma
1
Prostatic Neoplasms
1
Pregnancy Complications
1
Postoperative Hemorrhage
1
Postoperative Complications
1
Neoplasms
1
Nausea
1
Myofibroma
1
Myasthenia Gravis
1
Microbiota
1
Melanoma
1
Lymphangioma
1
Infertility, Female
1
Hepatitis B
1
Hand-Foot Skin Reaction (HFSR)
1
Glioblastoma
1
Erectile Dysfunction
1
Carcinoma, Non-Small-Cell Lung
1
Blood Loss, Surgical
1
Interventions
Pyridostigmine Bromide
4
Tacrolimus
2
Prednisone
2
Mycophenolic Acid
2
tocilizumab
1
sargramostim
1
Thymectomy
1
Tablets
1
Steroids
1
Sternotomy
1
Rituximab
1
Methylprednisolone
1
Methotrexate
1
Immunosuppressive Agents
1
Immunoglobulins, Intravenous
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Exercise
1
Data Collection
1
Cyclosporine
1
Cyclophosphamide
1
Azathioprine
1
Amifampridine
1
Alkalies
1
Albuterol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Myasthenia Gravis
×
Tablets
×
Clear all
NCT03914638
2020-04-06
BETA-MG
University of Aarhus
Phase 2/3
Unknown
30 enrolled